Protecting the confidentiality of interim data: addressing current challenges

Area of Science:

• Clinical Trials
• Cardiovascular Medicine
• Pharmacovigilance

Background:

• Confidentiality of interim data is vital for unbiased clinical trial outcomes.
• Challenging settings require innovative methods to maintain data integrity.
• Cardiovascular safety trials in type 2 diabetes mellitus present unique confidentiality challenges.

Purpose of the Study:

• To highlight the necessity of maintaining interim data confidentiality in clinical trials.
• To propose active strategies for safeguarding trial integrity.
• To address the specific challenges in cardiovascular safety trials for type 2 diabetes mellitus.

Main Methods:

• Implementing a Data Access Plan to restrict access to interim data.
• Developing a Performance Standards Document to pre-specify trial conduct targets.
• Establishing oversight procedures to monitor performance and address breaches.

Main Results:

• Data Access Plans prevent premature release of sensitive interim findings.
• Performance Standards Documents ensure trial recruitment, adherence, and retention targets are met.
• Proactive oversight allows for early detection and mitigation of confidentiality breaches.

Conclusions:

• Active, creative approaches are essential for maintaining confidentiality in clinical trials.
• Data Access Plans and Performance Standards Documents are key tools for trial integrity.
• Protecting interim data ensures reliable benefit-to-risk assessments and regulatory decision-making.